ClinicalTrials.Veeva

Menu

Clinical Trial of Zocor (Simvastatin) and Vytorin (Ezetimibe/Simvastatin) in Adolescents With Type 1 Diabetes

University of Colorado Denver (CU Denver) logo

University of Colorado Denver (CU Denver)

Status and phase

Completed
Phase 2

Conditions

Type 1 Diabetes Mellitus
Dyslipidemia

Treatments

Drug: Simvastatin
Drug: Ezetimibe/Simvastatin

Study type

Interventional

Funder types

Other
Industry
NIH

Identifiers

NCT00477204
K23DK075360 (U.S. NIH Grant/Contract)
06-1036

Details and patient eligibility

About

The purpose of the study is to establish the safety of ezetimibe/simvastatin and simvastatin in adolescents with Type 1 Diabetes and to determine the amount of decrease in LDL-cholesterol.The study hypothesizes that simvastatin and ezetimibe/simvastatin will be safe in adolescents with Type 1 Diabetes and will lower LDL-cholesterol at 6 months.

Full description

Cardiovascular disease is the leading cause of death in people with type 1 diabetes mellitus (T1DM) and since atherosclerosis begins in childhood, data to inform clinicians as to appropriate dyslipidemia treatment in this high-risk population are of great public health importance. In this trial of lipid-lowering medications (Zocor [simvastatin], a statin, compared to Vytorin [ezetimibe/simvastatin], a combination of a statin and Zetia, a medication that blocks cholesterol absorption) will be performed in patients ages 12-18 years with LDL ≥ 130 mg/dl, consistent with current ADA guidelines. The study hypothesizes that Zocor and Vytorin will be safe in adolescents with T1DM and will lower LDL-cholesterol at 6 months compared to baseline. In a two-arm design, Vytorin will lower LDL-c more than monotherapy with Zocor.

Enrollment

9 patients

Sex

All

Ages

12 to 18 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • 12-18 years of age with Type 1 Diabetes and seen at the Barbara Davis Center for Childhood Diabetes
  • Positive diabetes auto-antibodies or provider diagnosed Type 1 Diabetes
  • LDL > 130 mg/dl.

Exclusion criteria

  • Familial hypercholesterolemia, Triglycerides (TG) > 400mg/dl
  • Type 1 Diabetes of less than three-month duration
  • HbA1c>9.5%
  • Abnormal thyroid function
  • Abnormal Creatine Kinase (CK) values (defined as > 10 times the upper limit of normal)
  • Abnormal liver function tests (ALT/AST) (defined as >3 times the upper limit of normal)
  • Pregnancy, and patients on oral contraceptives
  • All resources are in English. Spanish speakers will not be available for the follow-up calls.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Triple Blind

9 participants in 2 patient groups

Simvastatin
Active Comparator group
Description:
Zocor(simvastatin)(20 mg)daily for 6 months along with Placebo (sugar pill)of active comparator (Vytorin \[simvastatin\] + Zetia \[ezetimibe\].
Treatment:
Drug: Simvastatin
Ezetimibe/Simvastatin
Active Comparator group
Description:
Vytorin(simvastatin \[Zocor} + ezetimibe \[Zetia\])(20 mg)daily for 6 months along with placebo (sugar pill)of comparator (Vytorin \[simvastatin\]).
Treatment:
Drug: Ezetimibe/Simvastatin

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems